Arrowhead Pharmaceuticals Announces Topline Results For Phase 3 SHASTA-3 And SHASTA-4 Clinical Studies Of Plozasiran In Patients With Severe Hypertriglyceridemia; Observes Deep, Durable, And Consistent Median Triglyceride Reductions Of 79% And 81% From Baseline

Benzinga Newsdesk www.benzinga.com Positive 72.6%

Neg 0% Neu 0% Pos 72.6%

Statistically significant reduction in acute pancreatitis events versus placebo across the entire sHTG study population, with an unprecedented 100% event reduction in high-risk patients
Continued and consistent safety and tolerability profile with no new safety signals
Detailed results will be presented as a HOT LINE Late Breaker at the European Society of Cardiology (ESC) Congress on August 30, 2026

Comments

No comments yet. Be the first!